Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in "driver-negative" lung adenocarcinomas
Menée à partir d'échantillons tumoraux prélevés sur des patients atteints d'un adénocarcinome du poumon (non fumeurs et fumeurs modérés), cette étude évalue l'efficacité d'une technique de séquençage à haut débit pour identifier des anomalies génomiques susceptibles d'induire la prescription d'une thérapie ciblée chez des patients pour lesquels des tests préalables n'avaient détecté aucune anomalie de ce type
PURPOSE: Broad, hybrid capture-based next-generation sequencing (NGS), as a clinical test, uses less tissue to identify more clinically relevant genomic alterations compared to profiling with multiple non-NGS tests. We set out to determine the frequency of such genomic alterations via this approach in tumors where previous extensive non-NGS testing had not yielded a targetable driver alteration.
METHODS: We enrolled lung adenocarcinoma patients with a ≤15 pack-year smoking history whose tumors previously tested "negative" for alterations in 11 genes (mutations in EGFR, ERBB2, KRAS, NRAS, BRAF, MAP2K1, PIK3CA, and AKT1, and fusions involving ALK, ROS1, and RET) via multiple non-NGS methods. We performed hybridization capture of the coding exons of 287 cancer-related genes and 47 introns of 19 frequently rearranged genes and sequenced these to deep, uniform coverage.
RESULTS: Actionable genomic alterations with a targeted agent based on NCCN guidelines were identified in 26% (8/31: EGFR G719A, BRAF V600E, SOCS5-ALK, CLIP4-ALK, CD74-ROS1, KIF5B-RET [n=2], CCDC6-RET). 7 of these patients either received or are candidates for targeted therapy. Comprehensive genomic profiling using this method also identified a genomic alteration with a targeted agent available on a clinical trial in an additional 39% (12/31).
CONCLUSION: Broad, hybrid capture-based NGS identified actionable genomic alterations in 65% (95% CI 48-82%) of tumors from never or light smokers with lung cancers deemed without targetable genomic alterations by earlier extensive non-NGS testing. These findings support first-line profiling of lung adenocarcinomas using this approach as a more comprehensive and efficient strategy compared to non-NGS testing.
Clinical Cancer Research , article en libre accès, 2015